An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events

This study is an open-label, single-arm, non-randomized trial designed to evaluate the safety and preliminary efficacy of CRG-002 administered via portal vein infusion or transplantation beneath the anterior rectus sheath in patients with type 1 diabetes mellitus (T1DM) or pancreatogenic diabetes who have hypoglycemia unawareness or severe hypoglycemic events.

NCT Number	NCT07503028
Lead Sponsor	Celregen Therapeutics
Conditions	T1DM - Type 1 Diabetes Mellitus, Pancreatogenic Diabetes Mellitus
Enrollment	10 participants
Start Date	2025-10-17
Primary Completion	2028-01-18 (estimated)
Study Completion	2028-01-18 (estimated)
Updated on ClinicalTrials.gov	2026-03-31